Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease.

McDonald-Hyman C, Muller JT, Loschi M, Thangavelu G, Saha A, Kumari S, Reichenbach DK, Smith MJ, Zhang G, Koehn BH, Lin J, Mitchell JS, Fife BT, Panoskaltsis-Mortari A, Feser CJ, Kirchmeier AK, Osborn MJ, Hippen KL, Kelekar A, Serody JS, Turka LA, Munn DH, Chi H, Neubert TA, Dustin ML, Blazar BR.

J Clin Invest. 2018 Oct 1;128(10):4604-4621. doi: 10.1172/JCI95713. Epub 2018 Aug 14.

2.

The purinergic receptor P2RX7 directs metabolic fitness of long-lived memory CD8+ T cells.

Borges da Silva H, Beura LK, Wang H, Hanse EA, Gore R, Scott MC, Walsh DA, Block KE, Fonseca R, Yan Y, Hippen KL, Blazar BR, Masopust D, Kelekar A, Vulchanova L, Hogquist KA, Jameson SC.

Nature. 2018 Jul;559(7713):264-268. doi: 10.1038/s41586-018-0282-0. Epub 2018 Jul 4.

PMID:
29973721
3.

Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37.

Sarhan D, Hippen KL, Lemire A, Hying S, Luo X, Lenvik T, Curtsinger J, Davis Z, Zhang B, Cooley S, Cichocki F, Blazar BR, Miller JS.

Cancer Immunol Res. 2018 Jul;6(7):766-775. doi: 10.1158/2326-6066.CIR-17-0498. Epub 2018 May 21.

PMID:
29784636
4.

miR-142-3p regulates autophagy by targeting ATG16L1 in thymic-derived regulatory T cell (tTreg).

Lu Y, Gao J, Zhang S, Gu J, Lu H, Xia Y, Zhu Q, Qian X, Zhang F, Zhang C, Shen H, Hippen KL, Blazar BR, Lu L, Wang X.

Cell Death Dis. 2018 Feb 19;9(3):290. doi: 10.1038/s41419-018-0298-2.

5.

Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease.

Hippen KL, Loschi M, Nicholls J, MacDonald KPA, Blazar BR.

Front Immunol. 2018 Jan 31;9:57. doi: 10.3389/fimmu.2018.00057. eCollection 2018. Review.

6.

Human in vitro-induced regulatory T cells display Dlgh1dependent and PKC-θ restrained suppressive activity.

Zanin-Zhorov A, Kumari S, Hippen KL, Merkel SC, MacMillan ML, Blazar BR, Dustin ML.

Sci Rep. 2017 Jun 26;7(1):4258. doi: 10.1038/s41598-017-04053-5.

7.

A robust in vitro model for trans-lymphatic endothelial migration.

Xiong Y, Brinkman CC, Famulski KS, Mongodin EF, Lord CJ, Hippen KL, Blazar BR, Bromberg JS.

Sci Rep. 2017 May 9;7(1):1633. doi: 10.1038/s41598-017-01575-w.

8.

In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines.

Hippen KL, O'Connor RS, Lemire AM, Saha A, Hanse EA, Tennis NC, Merkel SC, Kelekar A, Riley JL, Levine BL, June CH, Turka LA, Kean LS, MacMillan ML, Miller JS, Wagner JE, Munn DH, Blazar BR.

Am J Transplant. 2017 Dec;17(12):3098-3113. doi: 10.1111/ajt.14338. Epub 2017 Jun 14.

PMID:
28470889
9.

Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials.

McKenna DH Jr, Sumstad D, Kadidlo DM, Batdorf B, Lord CJ, Merkel SC, Koellner CM, Curtsinger JM, June CH, Riley JL, Levine BL, Miller JS, Brunstein CG, Wagner JE, Blazar BR, Hippen KL.

Cytotherapy. 2017 Feb;19(2):250-262. doi: 10.1016/j.jcyt.2016.10.011. Epub 2016 Nov 22.

10.

Preclinical Testing of Antihuman CD28 Fab' Antibody in a Novel Nonhuman Primate Small Animal Rodent Model of Xenogenic Graft-Versus-Host Disease.

Hippen KL, Watkins B, Tkachev V, Lemire AM, Lehnen C, Riddle MJ, Singh K, Panoskaltsis-Mortari A, Vanhove B, Tolar J, Kean LS, Blazar BR.

Transplantation. 2016 Dec;100(12):2630-2639. doi: 10.1097/TP.0000000000001465.

11.

Toward revision of antimicrobial therapies in hematopoietic stem cell transplantation: target the pathogens, but protect the indigenous microbiota.

Khoruts A, Hippen KL, Lemire AM, Holtan SG, Knights D, Young JH.

Transl Res. 2017 Jan;179:116-125. doi: 10.1016/j.trsl.2016.07.013. Epub 2016 Jul 25. Review.

12.

miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency.

Lu Y, Hippen KL, Lemire AL, Gu J, Wang W, Ni X, Ranganathan P, Levine BL, Riley JL, June CH, Turka LA, Munn DH, Garzon R, Lu L, Blazar BR.

Blood. 2016 Sep 8;128(10):1424-35. doi: 10.1182/blood-2016-05-714535. Epub 2016 Aug 2.

13.

Human CD39hi regulatory T cells present stronger stability and function under inflammatory conditions.

Gu J, Ni X, Pan X, Lu H, Lu Y, Zhao J, Guo Zheng S, Hippen KL, Wang X, Lu L.

Cell Mol Immunol. 2017 Jun;14(6):521-528. doi: 10.1038/cmi.2016.30. Epub 2016 Jul 4.

14.

Treg engage lymphotoxin beta receptor for afferent lymphatic transendothelial migration.

Brinkman CC, Iwami D, Hritzo MK, Xiong Y, Ahmad S, Simon T, Hippen KL, Blazar BR, Bromberg JS.

Nat Commun. 2016 Jun 21;7:12021. doi: 10.1038/ncomms12021.

15.

Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect.

Brunstein CG, Miller JS, McKenna DH, Hippen KL, DeFor TE, Sumstad D, Curtsinger J, Verneris MR, MacMillan ML, Levine BL, Riley JL, June CH, Le C, Weisdorf DJ, McGlave PB, Blazar BR, Wagner JE.

Blood. 2016 Feb 25;127(8):1044-51. doi: 10.1182/blood-2015-06-653667. Epub 2015 Nov 12.

16.

Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases.

Osborn MJ, Webber BR, Knipping F, Lonetree CL, Tennis N, DeFeo AP, McElroy AN, Starker CG, Lee C, Merkel S, Lund TC, Kelly-Spratt KS, Jensen MC, Voytas DF, von Kalle C, Schmidt M, Gabriel R, Hippen KL, Miller JS, Scharenberg AM, Tolar J, Blazar BR.

Mol Ther. 2016 Mar;24(3):570-81. doi: 10.1038/mt.2015.197. Epub 2015 Oct 27.

17.

Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism.

Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, Chen W, Scher JU, Mo R, Depoil D, Rao N, Liu B, Wei J, Lucas S, Koslow M, Roche M, Schueller O, Weiss S, Poyurovsky MV, Tonra J, Hippen KL, Dustin ML, Blazar BR, Liu CJ, Waksal SD.

Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16814-9. doi: 10.1073/pnas.1414189111. Epub 2014 Nov 10.

18.

Adoptive transfer of umbilical cord blood-derived regulatory T cells and early viral reactivation.

Brunstein CG, Blazar BR, Miller JS, Cao Q, Hippen KL, McKenna DH, Curtsinger J, McGlave PB, Wagner JE.

Biol Blood Marrow Transplant. 2013 Aug;19(8):1271-3. doi: 10.1016/j.bbmt.2013.06.004. Epub 2013 Jun 25. No abstract available.

19.

Scaffold protein Disc large homolog 1 is required for T-cell receptor-induced activation of regulatory T-cell function.

Zanin-Zhorov A, Lin J, Scher J, Kumari S, Blair D, Hippen KL, Blazar BR, Abramson SB, Lafaille JJ, Dustin ML.

Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1625-30. doi: 10.1073/pnas.1110120109. Epub 2012 Jan 17.

20.

Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes.

Hippen KL, Bucher C, Schirm DK, Bearl AM, Brender T, Mink KA, Waggie KS, Peffault de Latour R, Janin A, Curtsinger JM, Dillon SR, Miller JS, Socie G, Blazar BR.

Blood. 2012 Jan 12;119(2):619-28. doi: 10.1182/blood-2011-07-368027. Epub 2011 Nov 10.

21.

Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation.

Beyer M, Thabet Y, Müller RU, Sadlon T, Classen S, Lahl K, Basu S, Zhou X, Bailey-Bucktrout SL, Krebs W, Schönfeld EA, Böttcher J, Golovina T, Mayer CT, Hofmann A, Sommer D, Debey-Pascher S, Endl E, Limmer A, Hippen KL, Blazar BR, Balderas R, Quast T, Waha A, Mayer G, Famulok M, Knolle PA, Wickenhauser C, Kolanus W, Schermer B, Bluestone JA, Barry SC, Sparwasser T, Riley JL, Schultze JL.

Nat Immunol. 2011 Aug 14;12(9):898-907. doi: 10.1038/ni.2084.

22.

Clinical perspectives for regulatory T cells in transplantation tolerance.

Hippen KL, Riley JL, June CH, Blazar BR.

Semin Immunol. 2011 Dec;23(6):462-8. doi: 10.1016/j.smim.2011.07.008. Epub 2011 Aug 5. Review.

23.

Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity.

Hippen KL, Merkel SC, Schirm DK, Sieben CM, Sumstad D, Kadidlo DM, McKenna DH, Bromberg JS, Levine BL, Riley JL, June CH, Scheinberg P, Douek DC, Miller JS, Wagner JE, Blazar BR.

Sci Transl Med. 2011 May 18;3(83):83ra41. doi: 10.1126/scitranslmed.3001809.

24.

Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease.

Hippen KL, Merkel SC, Schirm DK, Nelson C, Tennis NC, Riley JL, June CH, Miller JS, Wagner JE, Blazar BR.

Am J Transplant. 2011 Jun;11(6):1148-57. doi: 10.1111/j.1600-6143.2011.03558.x. Epub 2011 May 12.

25.

Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.

Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, Defor T, Levine BL, June CH, Rubinstein P, McGlave PB, Blazar BR, Wagner JE.

Blood. 2011 Jan 20;117(3):1061-70. doi: 10.1182/blood-2010-07-293795. Epub 2010 Oct 15.

26.

Protein kinase C-theta mediates negative feedback on regulatory T cell function.

Zanin-Zhorov A, Ding Y, Kumari S, Attur M, Hippen KL, Brown M, Blazar BR, Abramson SB, Lafaille JJ, Dustin ML.

Science. 2010 Apr 16;328(5976):372-6. doi: 10.1126/science.1186068. Epub 2010 Mar 25. Erratum in: Science. 2010 May 21;328(5981):974.

27.

Immune regulatory cells in umbilical cord blood: T regulatory cells and mesenchymal stromal cells.

Tolar J, Hippen KL, Blazar BR.

Br J Haematol. 2009 Oct;147(2):200-6. doi: 10.1111/j.1365-2141.2009.07781.x. Review.

28.

Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells.

Hippen KL, Harker-Murray P, Porter SB, Merkel SC, Londer A, Taylor DK, Bina M, Panoskaltsis-Mortari A, Rubinstein P, Van Rooijen N, Golovina TN, Suhoski MM, Miller JS, Wagner JE, June CH, Riley JL, Blazar BR.

Blood. 2008 Oct 1;112(7):2847-57. doi: 10.1182/blood-2008-01-132951. Epub 2008 Jul 21.

29.

B cell receptor basal signaling regulates antigen-induced Ig light chain rearrangements.

Schram BR, Tze LE, Ramsey LB, Liu J, Najera L, Vegoe AL, Hardy RR, Hippen KL, Farrar MA, Behrens TW.

J Immunol. 2008 Apr 1;180(7):4728-41.

30.

Attenuation of IL-7 receptor signaling is not required for allelic exclusion.

Will WM, Aaker JD, Burchill MA, Harmon IR, O'Neil JJ, Goetz CA, Hippen KL, Farrar MA.

J Immunol. 2006 Mar 15;176(6):3350-5.

31.

Genomic view of systemic autoimmunity in MRLlpr mice.

Liu J, Karypis G, Hippen KL, Vegoe AL, Ruiz P, Gilkeson GS, Behrens TW.

Genes Immun. 2006 Mar;7(2):156-68.

PMID:
16508641
32.

In vivo assessment of the relative contributions of deletion, anergy, and editing to B cell self-tolerance.

Hippen KL, Schram BR, Tze LE, Pape KA, Jenkins MK, Behrens TW.

J Immunol. 2005 Jul 15;175(2):909-16.

33.

Progress towards understanding the genetic pathogenesis of systemic lupus erythematosus.

Behrens TW, Graham RR, Kyogoku C, Baechler EC, Ramos PS, Gillett C, Bauer J, Ortmann WA, Hippen KL, Peterson E, Langefeld CD, Moser KL, Gaffney PM, Gregersen PK.

Novartis Found Symp. 2005;267:145-60; discussion 160-4.

PMID:
15999805
34.

Basal immunoglobulin signaling actively maintains developmental stage in immature B cells.

Tze LE, Schram BR, Lam KP, Hogquist KA, Hippen KL, Liu J, Shinton SA, Otipoby KL, Rodine PR, Vegoe AL, Kraus M, Hardy RR, Schlissel MS, Rajewsky K, Behrens TW.

PLoS Biol. 2005 Mar;3(3):e82. Epub 2005 Mar 8.

35.

Fatal acute lymphoblastic leukemia in mice transgenic for B cell-restricted bcl-xL and c-myc.

Swanson PJ, Kuslak SL, Fang W, Tze L, Gaffney P, Selby S, Hippen KL, Nunez G, Sidman CL, Behrens TW.

J Immunol. 2004 Jun 1;172(11):6684-91.

36.
37.

Visualization of the genesis and fate of isotype-switched B cells during a primary immune response.

Pape KA, Kouskoff V, Nemazee D, Tang HL, Cyster JG, Tze LE, Hippen KL, Behrens TW, Jenkins MK.

J Exp Med. 2003 Jun 16;197(12):1677-87. Epub 2003 Jun 9.

38.

Ig light chain receptor editing in anergic B cells.

Tze LE, Baness EA, Hippen KL, Behrens TW.

J Immunol. 2000 Dec 15;165(12):6796-802.

39.

CD5 maintains tolerance in anergic B cells.

Hippen KL, Tze LE, Behrens TW.

J Exp Med. 2000 Mar 6;191(5):883-90.

40.

Fc gammaRIIB1 inhibition of BCR-mediated phosphoinositide hydrolysis and Ca2+ mobilization is integrated by CD19 dephosphorylation.

Hippen KL, Buhl AM, D'Ambrosio D, Nakamura K, Persin C, Cambier JC.

Immunity. 1997 Jul;7(1):49-58.

41.

Distinct mechanisms mediate SHC association with the activated and resting B cell antigen receptor.

D'Ambrosio D, Hippen KL, Cambier JC.

Eur J Immunol. 1996 Aug;26(8):1960-5.

PMID:
8765045
42.

Human and mouse killer-cell inhibitory receptors recruit PTP1C and PTP1D protein tyrosine phosphatases.

Olcese L, Lang P, Vély F, Cambiaggi A, Marguet D, Bléry M, Hippen KL, Biassoni R, Moretta A, Moretta L, Cambier JC, Vivier E.

J Immunol. 1996 Jun 15;156(12):4531-4.

PMID:
8648092
43.

Recruitment and activation of PTP1C in negative regulation of antigen receptor signaling by Fc gamma RIIB1.

D'Ambrosio D, Hippen KL, Minskoff SA, Mellman I, Pani G, Siminovitch KA, Cambier JC.

Science. 1995 Apr 14;268(5208):293-7.

PMID:
7716523
44.

Acidic residues are involved in substrate recognition by two soluble protein tyrosine phosphatases, PTP-5 and rrbPTP-1.

Hippen KL, Jakes S, Richards J, Jena BP, Beck BL, Tabatabai LB, Ingebritsen TS.

Biochemistry. 1993 Nov 23;32(46):12405-12.

PMID:
8241130

Supplemental Content

Loading ...
Support Center